CanaryIQ uses privacy-friendly, cookieless analytics (Fathom) to understand aggregate site usage. We don't use tracking cookies, we don't sell or share your data, and we honor Global Privacy Control. See our Privacy Policy.

Category thesis

high conviction 29 technologies

Biotechnology & Health

Biotechnology is entering a golden age where gene editing, mRNA, and AI-driven drug discovery are converging; the first approved CRISPR therapy proved the clinical thesis, and 250+ trials are underway.

The thesis

Category overview

CRISPR's first approved therapy (Casgevy, 2023) proved clinical viability. 250+ gene editing trials active. GLP-1 agonists are the biggest pharmaceutical story of the decade ($100B+ market). AI is accelerating drug discovery — Nvidia's $1B Eli Lilly partnership, Novo Nordisk + OpenAI. The convergence of gene editing, mRNA, and AI is creating a golden age of therapeutic innovation.

Technologies tracked

29 total

AI-driven drug discovery Biomanufacturing Bioprinting Brain-computer interfaces CAR-T cell therapy Cell and gene therapy manufacturing Cellular agriculture CRISPR gene editing Digital health and telemedicine Digital therapeutics Epigenetic editing Gene drives Gene sequencing GLP-1 receptor agonists Liquid biopsy Longevity science Microbiome therapeutics mRNA therapeutics Organoids Organs-on-chips Precision fermentation Protein engineering Psychedelic medicine Radiopharmaceuticals RNA therapeutics Spatial biology Synthetic biology Wearable health technology Xenotransplantation

The rest is inside

The full signal stack, KPIs and catalysts — live.

Every position is backed by talent flows, research and patent velocity, operational signals and a dated catalyst calendar. Log in to CanaryIQ to read the full analysis behind the verdict.